Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Rezolute, Inc.RZLT · Entity 1990 | Director | December 16, 2025 | December 17, 2025 |
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Chief Operating Officer | October 04, 2019 | October 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Rezolute, Inc.
Report date December 16, 2025 · Filed December 17, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 119,675 |
Reported balance
After 2025-12-16 transaction · row 1
1 source rowRow 1 · 2025-12-16 · Purchase · Acquired 5,650 · Balance 119,675 |
Ultragenyx Pharmaceutical Inc.
Report date October 04, 2019 · Filed October 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,703 |
Reported balance
After 2019-10-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-10-04 · Tax withholding · Disposed 1,297 · Balance 18,703 F1: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs.
F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 16, 2025 Filed Dec 17, 2025 21:14 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 5,650 | $1.69 | $9,548.50 |
DisclosureSEC source: 0000912282-25-001429 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,675 Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:17 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $10.16 | $0.00 |
DisclosureSEC source: 0000912282-25-001288 · form4.xml · derivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2035-11-19 F2 · derivative.exercise_date: The options fully vest on December 1, 2026. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 22:17 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 21,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-001288 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,025 F1 · shares: Represents grant of restricted stock units which fully vest on December 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 13:58 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000663 · form4.xml · derivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 5,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: The options vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 13:58 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000663 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,025 F1 · shares: Represents grant of restricted stock units which vest 100% on July 1, 2026. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 19:52 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 6,758 | $2.92 | $19,733.36 |
DisclosureSEC source: 0000912282-25-000349 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,025 Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 00:59 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Shares | 10,000 | $4.70 | $47,000.00 |
DisclosureSEC source: 0000912282-25-000188 · form4.xml · nonDerivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,267 F3 · price: The purchase price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.70, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 16, 2025 Filed Feb 21, 2025 00:59 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000188 · form4.xml · derivative · entry 3 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-02-16 F2 · derivative.exercise_date: The options vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 21, 2025 00:59 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantCommon Shares | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000188 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,267 F1 · shares: Represents grant of restricted stock units which vest 100% on March 1, 2026. Read SEC document |
| September 24, 2024 Filed Sep 24, 2024 21:14 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Stock | 4,259 | $4.70 | $20,017.30 |
DisclosureSEC source: 0000912282-24-000676 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,767 Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 18:00 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Stock | 4,815 | $4.15 | $19,982.25 |
DisclosureSEC source: 0000912282-24-000502 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,508 Read SEC document |
| January 23, 2024 Filed Jan 25, 2024 17:10 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantDirector Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $1.02 | $0.00 |
DisclosureSEC source: 0000912282-24-000081 · form4.xml · derivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2034-01-23 F1 · derivative.exercise_date: The options vest in 36 equal monthly installments, beginning February 23, 2024. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 22:08 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013413 · doc1.xml · derivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Option shall vest on the first day of the month following the Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| May 04, 2022 Filed May 6, 2022 21:14 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Stock | 25,000 | $3.80 | $95,000.00 |
DisclosureSEC source: 0001567619-22-009698 · doc1.xml · nonDerivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,693 F1 · kind: The Reporting Person acquired these shares of common stock in connection with the Issuer's closing of registered direct public offering on May 4, 2022. Read SEC document |
| October 15, 2021 Filed May 6, 2022 21:14 UTC | Rezolute, Inc. RZLT · Entity 1990 | PurchaseCommon Stock | 7,693 | $6.50 | $50,004.50 |
DisclosureSEC source: 0001567619-22-009698 · doc1.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,693 Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 01:11 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-013443 · doc1.xml · derivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following Grant Date and each month thereafter on the first day of each month until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| October 04, 2019 Filed Oct 7, 2019 23:40 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 1,297 | $44.52 | $57,742.44 |
DisclosureSEC source: 0001209191-19-052722 · doc4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,703 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:07 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 11,000 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-015740 · doc4.xml · derivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:07 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015740 · doc4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 20:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $77.30 | $0.00 |
DisclosureSEC source: 0001209191-18-054519 · doc4.xml · derivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-10-04 F2 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| October 04, 2018 Filed Oct 9, 2018 20:23 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-054519 · doc4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.